Ann: Investor Webinar Presentation, page-65

It's interesting, that before each capital raise the chatter about Kidder Williams and a strategic partnership increases so much , hmmm

here is what my GPT has spit out




“Things You Might Not Know Yet” (But Are Publicly Discussed in Certain Circles)

• Ongoing Observational Studies: Beyond formal clinical trials, the company may collaborate with hospitals to collect real-world evidence of OncoSil’s benefits and safety. Such observational data can bolster health economics and reimbursement arguments.

• Potential for Asia-Pacific Licensing: There has been investor speculation that OncoSil Medical could enter partnership or licensing agreements in Asia (where pancreatic cancer incidence is high). While not confirmed, such deals could be a key part of its growth strategy.

• PanCO Trial Insights: The earlier PanCO study informed CE Mark approval, showing improvement in local disease control. Watch for any follow-up data that might further validate survival benefits in combination with chemotherapy.

• Future Pipeline: Although the pancreatic cancer application has taken precedence, there is potential for OncoSil to be tested in secondary liver cancers or primary liver tumours, given the localised radiation approach.

...